NIH VideoCast - Psoriasis as a Model to Study Inflammation and Cardiometabolic Diseases in Humans

Skip Navigation

Psoriasis as a Model to Study Inflammation and Cardiometabolic Diseases in Humans

Loading... Loading video...

277 Views

Air date:	Friday, October 22, 2021, 12:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 277 (130 Live, 147 On-demand)
Category:	NIH Director's Seminars
Runtime:	00:58:51
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director's Seminar Series Inflammation is critical to atherosclerosis initiation, progression and complications. The goal of The Laboratory of Inflammation and Cardiometabolic Diseases, NHLBI, is to understand how chronic systemic inflammation drives development of cardiometabolic diseases in humans. Dr. Mehta’s research program has utilized psoriasis, a chronic inflammatory skin disease, as a model to probe inflammatory, lipid and metabolic pathways associated with atherosclerosis progression. In 2012, Dr. Mehta founded the Psoriasis Atherosclerosis Cardiometabolic Initiative (PACI) at the NHLBI Intramural Program when he was awarded the Inaugural Lasker Clinical Scholar Award. Dr. Mehta has followed over 350 patients with psoriasis for at least four years, with very high follow up rates for vascular imaging by coronary CT angiography (CTA) and FDG PET/CT coupled with flow cytometry and in vitro cellular-based immunologic studies. These systematic, serial imaging and laboratory-based studies have provided a powerful framework to understand how inflammation drives coronary plaque progression as compared to coronary artery disease. Dr. Mehta’s group found that poor vascular health begins in psoriasis a decade earlier than in those without psoriasis, and that treatment of skin disease is associated with improvement in vascular disease. When severe psoriasis is treated with biologic therapy, there is a reduction in coronary inflammation by perivascular fat attenuation index, a reduction in non-calcified coronary plaque burden, and coronary plaque lipid-rich necrotic core after one-year of treatment. All of these are important features of coronary plaques that lead to heart attacks. Dr. Mehta’s will present a real-life clinical case of a patient with moderate to severe psoriasis, and examples of scientific advancements that have changed clinical practice guidelines to improve the cardiovascular care of patients with inflammatory diseases.

NLM Title:	Psoriasis as a model to study inflammation and cardiometabolic diseases in humans / Nehal Mehta.
Author:	Mehta, Nehal N. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): NIH Director's Seminar Series Inflammation is critical to atherosclerosis initiation, progression and complications. The goal of The Laboratory of Inflammation and Cardiometabolic Diseases, NHLBI, is to understand how chronic systemic inflammation drives development of cardiometabolic diseases in humans. Dr. Mehta's research program has utilized psoriasis, a chronic inflammatory skin disease, as a model to probe inflammatory, lipid and metabolic pathways associated with atherosclerosis progression. In 2012, Dr. Mehta founded the Psoriasis Atherosclerosis Cardiometabolic Initiative (PACI) at the NHLBI Intramural Program when he was awarded the Inaugural Lasker Clinical Scholar Award. Dr. Mehta has followed over 350 patients with psoriasis for at least four years, with very high follow up rates for vascular imaging by coronary CT angiography (CTA) and FDG PET/CT coupled with flow cytometry and in vitro cellular-based immunologic studies. These systematic, serial imaging and laboratory-based studies have provided a powerful framework to understand how inflammation drives coronary plaque progression as compared to coronary artery disease. Dr. Mehta's group found that poor vascular health begins in psoriasis a decade earlier than in those without psoriasis, and that treatment of skin disease is associated with improvement in vascular disease. When severe psoriasis is treated with biologic therapy, there is a reduction in coronary inflammation by perivascular fat attenuation index, a reduction in non-calcified coronary plaque burden, and coronary plaque lipid-rich necrotic core after one-year of treatment. All of these are important features of coronary plaques that lead to heart attacks. Dr. Mehta will present a real-life clinical case of a patient with moderate to severe psoriasis, and examples of scientific advancements that have changed clinical practice guidelines to improve the cardiovascular care of patients with inflammatory diseases.
Subjects:	Inflammation--physiopathology Metabolic Syndrome--complications Models, Biological Psoriasis--etiology
Publication Types:	Lecture Webcast

NLM Classification:	WR 205
NLM ID:	9918299483706676
CIT Live ID:	43964
Permanent link:	https://videocast.nih.gov/watch=43964

Related Videos...